119 related articles for article (PubMed ID: 37589434)
1. The risk of weekend biopsy: Impact of specimen source and fixation status on HER2 assessment in the treatment of advanced gastric cancer (The HER_WEEKEND study).
Nakamura M; Watanabe A; Yoshizawa A; Iwasaki S; Nomura A; Matsumura M; Murai T; Itaya K; Koike Y; Izumi T; Endo A; Kato S; Ono Y; Ohshima T; Okazaki N; Nakagawa S; Ishii Y; Fukasawa Y; Yokota I; Tsuji T; Nishikawa S
Pathol Int; 2023 Oct; 73(10):509-519. PubMed ID: 37589434
[TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
3. Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH.
Kondo J; Yoshino S; Iida M; Takeda S; Nakashima C; Watanabe Y; Nishiyama M; Tokumitsu Y; Shindo Y; Nishimura T; Suzuki N; Hoshii Y; Itoh H; Nagano H
Anticancer Res; 2024 Feb; 44(2):621-630. PubMed ID: 38307565
[TBL] [Abstract][Full Text] [Related]
4. Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization.
Yamashita-Kashima Y; Shu S; Yorozu K; Hashizume K; Moriya Y; Fujimoto-Ouchi K; Harada N
Gastric Cancer; 2014 Oct; 17(4):638-47. PubMed ID: 24414131
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
7. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
Park SR; Park YS; Ryu MH; Ryoo BY; Woo CG; Jung HY; Lee JH; Lee GH; Kang YK
Eur J Cancer; 2016 Jan; 53():42-50. PubMed ID: 26693898
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
9. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.
Rottmann D; Assem H; Matsumoto N; Wong S; Hui P; Buza N
Int J Gynecol Pathol; 2021 May; 40(3):263-271. PubMed ID: 32897955
[TBL] [Abstract][Full Text] [Related]
10. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.
Tominaga N; Gotoda T; Hara M; Hale MD; Tsuchiya T; Matsubayashi J; Kono S; Kusano C; Itoi T; Fujimoto K; Moriyasu F; Grabsch HI
Gastric Cancer; 2016 Apr; 19(2):553-560. PubMed ID: 25987463
[TBL] [Abstract][Full Text] [Related]
11. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
Ahn S; Ahn S; Van Vrancken M; Lee M; Ha SY; Lee H; Min BH; Lee JH; Kim JJ; Choi S; Jung SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
Oncotarget; 2015 Nov; 6(35):38372-80. PubMed ID: 26460823
[TBL] [Abstract][Full Text] [Related]
12. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
[TBL] [Abstract][Full Text] [Related]
13. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
[TBL] [Abstract][Full Text] [Related]
14. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
15. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
[TBL] [Abstract][Full Text] [Related]
16. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
[TBL] [Abstract][Full Text] [Related]
17. HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.
Baretton G; Kreipe HH; Schirmacher P; Gaiser T; Hofheinz R; Berghäuser KH; Koch W; Künzel C; Morris S; Rüschoff J;
Virchows Arch; 2019 May; 474(5):551-560. PubMed ID: 30826877
[TBL] [Abstract][Full Text] [Related]
18. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
19. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer.
Oono Y; Kuwata T; Takashima K; Yoda Y; Ikematsu H; Shitara K; Kinoshita T; Yano T
Surg Endosc; 2018 Sep; 32(9):3964-3971. PubMed ID: 29500656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
